Prenatal Screening for Down Syndrome With DNAFirst (DNAFirst)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01966991|
Recruitment Status : Completed
First Posted : October 22, 2013
Last Update Posted : February 21, 2018
This study will explore how maternal plasma circulating cell free DNA (ccfDNA) can be used as a primary screening test for Down syndrome as part of routine clinical care in the general pregnancy population. Plasma ccfDNA testing is currently recommended only for use as a secondary screen for 'high-risk' women (i.e., women whose risk factors for trisomy make them candidates for invasive testing such as chorionic villous sampling or amniocentesis). Because most women in this 'high-risk' category are carrying unaffected fetuses, many 'unnecessary' procedures are completed in order to identify the few women whose fetuses have a chromosomal disorder. This creates expense, anxiety, and most importantly, loss of unaffected fetuses due to procedure related miscarriage. Plasma DNA testing is now being used to reduce significantly the number of women with unaffected fetuses undergoing invasive testing.
Applying such testing as a 'first-line' screen has not been well-explored, despite calls from several clinical professional societies to do so. The investigators intent is to introduce, under carefully monitored conditions, ccfDNA testing through Rhode Island primary prenatal practices to the general pregnancy population. Education/orientation of prenatal care providers, their staffs, and their patients will be carefully orchestrated, and implementation issues identified and addressed. Telephone surveys of consented patients will elicit responses to their understanding of the test, their satisfaction with the process, and a comparison of their experience with serum screening in a prior pregnancy. Knowledge gained from this study will help validate new screening paradigms involving ccfDNA testing. The study is not designed to estimate Down syndrome detection rates with any confidence, but can provide information on uptake rates, failure rates, screen positive rates, and the decision-making of women with positive test results.
|Condition or disease|
|Trisomy 21 Trisomy 18 Trisomy 13 Monosomy X|
Maternal plasma ccfDNA testing examines fragments of maternal and fetal (placental) DNA that are normally found in the mother's circulation. For any targeted chromosome (e.g., chromosome 21) an excess of fragments from that chromosome can strongly suggest trisomy in the fetus (e.g., trisomy 21 or Down syndrome). This technology has been available since late 2011 but is mainly offered in the 'high-risk setting with motivated patients, intensive education by genetic counselors and maternal-fetal medicine professionals, and low patient volumes. As a secondary screening test in high-risk women, this testing can reduce the frequency of invasive procedures by 90% or more compared to conventional serum screening. Since CVS and amniocentesis are associated with procedure-related fetal loss (an important factor among women refusing these procedures), the use of ccfDNA testing may result in an increase in the prenatal identification of affected fetuses in the high-risk population. However, this technology has not been studied in the general risk group where women usually have no known risk factors when presenting for prenatal care. The investigators' aim is to observe how prenatal practices in Rhode Island are able to offer this technology in place of conventional serum/ultrasound screening as early as 10 weeks of pregnancy. The investigators expect that clinicians and office staff will be challenged by this paradigm shift, as will their patients. The investigators intend to develop an education program for offices and introduce the new test - DNAFirst- methodically in the Women & Infants Hospital catchment area. The test uptake rate, reaction to its availability, and response to screen positive results will be monitored, along with other measures relevant to implementation and test performance. The investigators also will be surveying by telephone 100 women who have agreed to DNAFirst testing and to being contacted to determine their understanding of and satisfaction with the new test. Many factors may complicate this introduction and these will all need to be addressed. For example, a screen positive result on the DNAFirst test is associated with a much higher risk of aneuploidy(e.g., 1:2) than conventional serum screening. The DNAFirst test is also associated with a higher rate of test failure than serum screening. The DNAFirst testing protocol includes testing a buccal sample from the father of the baby when available. It will be important to gauge how offices and patients perceive and accept these changes.
Secondary screening in high-risk women using ccfDNA is becoming more commonplace and is more often covered by insurers. With expected price reductions due to improvements in sequencing technology, it is likely that in 12-18 months, insurance coverage for ccfDNA testing will become more routine. In such a setting expected test uptake and patient decision-making would not be influenced by the limited insurance currently available. The investigators want to simulate the patient's cost of ccfDNA testing to be similar to that currently encountered for serum screening. Towards that end, Natera, Inc., a Clinical Laboratory Improvement Act certified laboratory in San Carlos, California, has agreed to underwrite the cost of ccfDNA testing during the study period. By identifying factors influencing patient acceptance and understanding how patients and providers view this new paradigm compared to established serum and sonographic screening, this project will provide unbiased evidence regarding implementation of ccfDNA testing in a general pregnancy population that could translate into nationwide practice.
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||DNAFirst: Primary Screening for Down Syndrome by Maternal Plasma DNA|
|Study Start Date :||June 2014|
|Actual Primary Completion Date :||July 2015|
|Actual Study Completion Date :||December 2015|
Surveyed DNAFirst users
Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
- Patient satisfaction with ccfDNA testing as a primary screen for aneuploidy [ Time Frame: within 90 days of receiving ccfDNA screening results ]A telephone survey will be administered to women who have undergone ccfDNA testing (DNAFirst) and who have provided written permission to be contacted specifically for this purpose.Included will be questions designed to elicit understanding of the results, implications of positive and negative results, comparison with earlier serum-screening experience, and reasons for accepting/declining ancillary testing (sex aneuploidy).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01966991
|United States, Rhode Island|
|Women & Infants Hospital of Rhode Island|
|Providence, Rhode Island, United States, 02905|
|Principal Investigator:||Glenn E Palomaki, PhD||Women and Infants Hospital of Rhode Island|